LBX(SH:603883)2022-04-28 16:00Financial Performance - The company's revenue for Q1 2022 was RMB 4,140,649,849, representing a year-on-year increase of 13.81%[4] - The net profit attributable to shareholders was RMB 241,794,170, reflecting a growth of 6.26% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was RMB 216,150,393, which increased by 12.75% year-on-year[4] - The basic and diluted earnings per share were both RMB 0.53, a decrease of 4.01% year-on-year[5] - The weighted average return on equity was 4.30%, down by 0.20 percentage points from the previous year[5] - Total revenue for the first quarter of 2022 reached CNY 4,140,649,849, representing a year-over-year increase of 13.81%[15] - Net profit for Q1 2022 was ¥270,602,719, compared to ¥256,973,163 in Q1 2021, representing a growth of 5.3%[28] - Total comprehensive income for the first quarter of 2022 was CNY 268,523,719, compared to CNY 256,973,163 in the same period of 2021, representing an increase of approximately 4.3%[29] - The net profit attributable to the parent company was CNY 239,715,170, up from CNY 227,543,757 in Q1 2021, indicating a growth of about 5.4%[29] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 41.62%, amounting to RMB 260,866,324, primarily due to reduced customer payments during the pandemic[4][8] - Cash inflows from operating activities totaled CNY 3,759,516,140, compared to CNY 4,147,766,316 in Q1 2021, showing a decline of about 9.4%[30] - Cash outflows from operating activities were CNY 3,498,649,816, resulting in a net cash flow from operating activities of CNY 260,866,324, down from CNY 446,879,815 in the same period last year[31] - The net increase in cash and cash equivalents for the period was CNY 930,149,004, contrasting with a decrease of CNY (218,087,712) in the same quarter of the previous year[31] - The ending balance of cash and cash equivalents was CNY 1,609,708,435, up from CNY 579,193,575 at the end of Q1 2021[31] Assets and Liabilities - Total assets at the end of the reporting period reached RMB 18,446,687,171, an increase of 8.78% from the end of the previous year[5] - The total liabilities decreased to ¥11,685,759,718 in Q1 2022 from ¥12,179,191,692 in Q1 2021, a reduction of 4.1%[25] - The equity attributable to shareholders increased by 44.82% to RMB 6,310,671,411 compared to the previous year[5] - The total assets increased to ¥18,446,687,171 in Q1 2022 from ¥16,958,085,717 in Q1 2021, marking a growth of 8.8%[25] Store Operations and Expansion - The total number of stores reached 8,612, with 6,242 direct stores and 2,370 franchise stores, adding 359 new stores during the reporting period[12] - The company completed a significant acquisition, purchasing 71.96% of Hunan Huairen Health Industry Development Co., Ltd. for RMB 1.637 billion, increasing its store count in Hunan to over 3,000[12] - The company added 156 new direct-operated stores in the first quarter, while closing 43 stores due to strategic adjustments[17] - The company completed three acquisition projects during the reporting period, totaling CNY 176,738,840, acquiring 758 pharmacies[20] Sales and Marketing - Online sales reached RMB 270 million, a remarkable year-on-year growth of 123%[13] - The company’s self-owned brand sales amounted to RMB 560 million, up 35.7% year-on-year, with a sales proportion exceeding 17.8%[13] - The company reported a total of 6.271 million members, with 1.68 million new members added in Q1 2022[13] - The company achieved a daily average revenue per square meter of CNY 60 across its direct-operated stores[19] Cost and Profitability - Total operating costs for Q1 2022 were ¥3,835,648,341, up from ¥3,358,435,538 in Q1 2021, reflecting a year-over-year increase of 14.2%[26] - Gross profit margin for the retail segment was 38.07%, an increase of 0.94% compared to the previous year[14] - The gross profit margin for Chinese medicine products was 52.73%, an increase of 0.30% year-over-year[15] - The total operating profit for Q1 2022 was ¥321,726,325, slightly up from ¥317,524,089 in Q1 2021, indicating stable operational performance[28] Future Outlook - Research and development expenses were not specified but are critical for future product development and market expansion strategies[28] - The company plans to continue focusing on market expansion and new product development to drive future growth[28]